Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 78.41M P/E - EPS this Y 44.90% Ern Qtrly Grth -
Income -96.02M Forward P/E -1.23 EPS next Y -4.10% 50D Avg Chg -27.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -32.00%
Dividend N/A Price/Book 0.43 EPS next 5Y - 52W High Chg -72.00%
Recommedations 2.00 Quick Ratio 8.52 Shares Outstanding 37.76M 52W Low Chg 18.00%
Insider Own 0.79% ROA -30.67% Shares Float 18.01M Beta 1.94
Inst Own 75.95% ROE -56.79% Shares Shorted/Prior 0.92M/633.55K Price 4.00
Gross Margin - Profit Margin - Avg. Volume 21,696 Target Price 17.00
Oper. Margin - Earnings Date May 9 Volume 8,992 Change -3.15%
About Solid Biosciences Inc.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Solid Biosciences Inc. News
04/03/24 Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/02/24 Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
04/01/24 Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
03/28/24 How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
03/27/24 Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
03/13/24 Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
03/07/24 Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
03/06/24 Solid Biosciences to Participate at Upcoming Investor Conferences
02/29/24 14 Stocks With Heavy Insider Buying In 2024
01/18/24 Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
01/17/24 Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up
01/16/24 Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
01/15/24 Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why
01/08/24 Solid Biosciences Announces $109 Million Private Placement
01/04/24 Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference
12/09/23 While institutions invested in Solid Biosciences Inc. (NASDAQ:SLDB) benefited from last week's 68% gain, private equity firms stood to gain the most
12/08/23 Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
12/07/23 Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003
11/22/23 Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference
11/17/23 The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics
SLDB Chatroom

User Image GreenwichCapital Posted - 6 hours ago

$SLDB I dumped 2/3. Too much pain

User Image Stock_Titan Posted - 2 weeks ago

$SLDB Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-k9p0e6i5a02y.html

User Image Baldmaster22 Posted - 2 weeks ago

$SLDB Can this get back to $15?

User Image GreenwichCapital Posted - 2 weeks ago

$SLDB

User Image Cebu5050 Posted - 2 weeks ago

$SLDB ☢️⚠️ get back 500 feet SLDB gonna EXPLODE 😱🤯🥳 BO knows bean town 😉👍

User Image BioTuesdays Posted - 2 weeks ago

William Blair launched coverage of Solid Biosciences with an “outperform” rating. The stock closed at $14.25 on March 27. $SLDB https://biotuesdays.com/2024/04/01/william-blair-starts-solid-biosciences-at-op/

User Image DonCorleone77 Posted - 2 weeks ago

$SLDB Solid Biosciences receives Rae Pediatric Disease designation for SGT-003 Solid Biosciences announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation for SGT-003, the company's next-generation Duchenne muscular dystrophy gene therapy candidate. The planned Phase 1/2 trial, INSPIRE Duchenne, is a first-in-human, open-label, multicenter trial to determine the safety and tolerability of SGT-003 in pediatric patients with DMD at a dose of 1E14vg/kg. SGT-003 will be administered as a one-time intravenous infusion to patients in two cohorts with a minimum of three patients each, with the potential for cohort expansion. Cohort 1 will study patients with DMD ages 4 to less than 6 and cohort 2 will study patients with DMD ages 6 to less than 8. We anticipate providing an initial safety update for the first three to four patients enrolled in the INSPIRE Duchenne trial in mid-2024...

User Image Stock_Titan Posted - 2 weeks ago

$SLDB Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 https://www.stocktitan.net/news/SLDB/solid-biosciences-receives-rare-pediatric-disease-designation-from-c9uc3dklwhcw.html

User Image StockMilo Posted - 03/31/24

$VINC I’m looking through other biotech SEC filings they all have lots of occasions where they file form 424B5 to allow them to sell stock at opportune moments. Examples include $SLDB https://investors.solidbio.com/static-files/69c03d27-e5b1-4e92-80f3-42621938a852 and $ATXS https://ir.astriatx.com/static-files/9dca2360-8dce-408a-bd59-d72ab9ee542c both of which ended up receiving private placement investments from Perceptive Advisors and other prominent institutional investors. So just because VINC files a 424B5 allowing them to sell up to $50m in common stock doesn’t mean they have to utilize it. It is just an option. Everyone knew they needed to raise capital. So any knee jerk sell off because of the filing is probably an opportunity ahead of some big data being revealed. Just my opinion

User Image Cpost2 Posted - 03/29/24

$SLDB https://www.investors.com/news/technology/biotech-stock-solid-biosciences-duchenne-muscular-dystrophy-gene-therapy/

User Image Cebu5050 Posted - 03/28/24

$SLDB go CELTICS 🍀

User Image Cpost2 Posted - 03/27/24

$SLDB Up 53% past month. Just getting started.

User Image Montygo2020 Posted - 03/27/24

$SLDB damn it I should have loaded up @13.25

User Image kubota2323 Posted - 03/27/24

$SLDB Nice.

User Image Stocks4thought Posted - 03/27/24

$SLDB Field and stream ot $LVTX $INDP $STOK $SLNO

User Image Stock_Titan Posted - 03/27/24

$SLDB Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium https://www.stocktitan.net/news/SLDB/solid-biosciences-to-participate-at-cantor-s-virtual-muscular-h32dzghrqzlc.html

User Image FyCkD_FuNnY Posted - 03/22/24

$VRDN Down 7% $SLDB Up 73% $FUSN Up 90% 2/3 Not Bad for 51 Days... Perceptive👈👀🦏

User Image Stocks4thought Posted - 03/22/24

$SLDB Girl got it going on 11/02/2023 11:34:10 Bought 2000 SLDB @ 2.7773 11/01/2023 10:57:18 Bought 2000 SLDB @ 2.455 others $MRKR $INDP $MAIA

User Image Jonrenie Posted - 03/21/24

$SLDB Convenient dips and rebounds seem to be quite common here eh?

User Image Stonksonomics Posted - 03/20/24

$SLDB Take me back to $100 a share

User Image Cpost2 Posted - 03/20/24

$SLDB We are getting a lot traction with larger investors. These investors are banking on positive outcomes and world wide distribution of life changing medical breakthroughs. $20 very soon.

User Image GreenwichCapital Posted - 4 weeks ago

$SLDB bought at the opening 13.23. Room to run. Great day plus I own Fusion.

User Image GreenwichCapital Posted - 4 weeks ago

$FUSN $SLDB reinvest profits from Fusion or hold out for the last 3 points?

User Image Trango Posted - 4 weeks ago

$SLDB 21$ is my break even. My last purchase was before RS on 21st Oct 2022 at 0,43$... I admire my patience 🤣

User Image Hartnett1987 Posted - 4 weeks ago

$SLDB been holding since $1.81 keep it moving

User Image Stocks4thought Posted - 4 weeks ago

$SLDB $17 tmrw others baking cakes $MRKR $VYGR $SLNO partials 2/01/2023 15:59:55 Bought 112 SLDB @ 3.0372 -340.17 0.00 0.00 12/01/2023 15:59:55 Bought 104 SLDB @ 3.0361 -315.75 0.00 0.00 12/01/2023 15:59:55 Bought 277 SLDB @ 3.03 -839.31 0.00 0.00 12/01/2023 15:59:55 Bought 900 SLDB @ 3.028 -2,725.20 0.00 0.00 12/04/2023 11:36:13 Bought 2000 SLDB @ 3.0876

User Image Stocks4thought Posted - 4 weeks ago

$SLDB $16 soon................ot $MRKR $VYGR $SLNO $PASG

User Image Stocks4thought Posted - 4 weeks ago

$MRKR Eclipse the $4.60 and we can take the bar car- back to $9...................ot $VYGR $STTK $SLDB $SLNO

User Image Stocks4thought Posted - 4 weeks ago

$SLDB $15 hole Ricky Fowler shout out!!!!!!!!!!!!!!!!!!!!!!!! ot $MAIA $LVTX $SLNO

User Image AnaChart Posted - 1 month ago

$SLDB https://anachart.com/wp-content/uploads/ana_temp/1710759677_soc-img.jpg

Analyst Ratings
William Blair Outperform Mar 28, 24
Barclays Overweight Mar 18, 24
Citigroup Buy Mar 15, 24
HC Wainwright & Co. Buy Mar 14, 24
Piper Sandler Overweight Mar 14, 24
HC Wainwright & Co. Buy Mar 11, 24
HC Wainwright & Co. Buy Dec 8, 23
Cantor Fitzgerald Overweight Sep 22, 23
Barclays Overweight Nov 11, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Ganot Ilan Director Director Jan 27 Sell 7.99 139 1,111 8,416 01/30/24
PERCEPTIVE ADVISORS LLC Director Director Jan 11 Buy 5.53 3,410,713 18,861,243 6,833,539 01/12/24
RA CAPITAL MANAGEMENT, L.P. Director Director Jan 11 Buy 5.53 904,160 5,000,005 4,192,216 01/12/24
Tan Kevin CFO & Treasurer CFO & Treasurer Jan 09 Sell 8.2 3,935 32,267 9,308 01/11/24
Ganot Ilan Director Director Jan 03 Sell 5.3 1,142 6,053 8,167 01/05/24
Ganot Ilan Director Director May 02 Sell 4.85 487 2,362 4,153 06/08/23
Morris Carl Ashley Chief Scientific Off.. Chief Scientific Officer Jan 27 Sell 7.49 441 3,303 19,760 01/31/23
Ganot Ilan Director Director Jan 27 Sell 7.49 1,523 11,407 84,591 01/31/23
Morris Carl Ashley Chief Scientific Off.. Chief Scientific Officer Mar 14 Sell 1.1 22,665 24,932 255,209 03/15/22
Schneider Joel Solomon Zev Chief Operating Offi.. Chief Operating Officer Mar 14 Sell 1.1 30,504 33,554 236,270 03/15/22